The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

AIMS Methotrexate is considered by many practitioners to be the agent of choice in the treatment of rheumatoid arthritis. The pharmacokinetics of methotrexate have been reported to exhibit significant intersubject variability. Therefore, this study was undertaken to evaluate the population pharmacokinetics of methotrexate during long-term administration in adults with rheumatoid arthritis. METHODS Methotrexate pharmacokinetics were evaluated in a 36 month study of 62 adults with rheumatoid arthritis. Patients received oral or intramuscular doses of methotrexate weekly with pharmacokinetic studies performed every 6 months. Data were analyzed with nonlinear mixed effects modeling. RESULTS Three thousand two hundred and sixty post oral or intramuscular dose serum methotrexate concentrations comprising 425 individual concentration vs time profiles were modeled using NONMEM. Covariates that significantly (P < 0.005) influenced the disposition of methotrexate were age (AGE, years), body weight (BW, kg), creatinine clearance (CL(CR), 1 h(-1)), gender (GEN; 0 = male, 1 = female), dose (DOSE, micromol), and fed vs fasted state (FED; 0 = fasted, 1 = fed). The final model describing the biexponential disposition of methotrexate was clearance(CL, 1 h(-1)) = (0.0810*BW + 0.257*CL(CR))*(1-(0.167*GEN); central volume (Vc, 1) = 0.311*BW; peripheral volume (Vp, 1) = 0.469*BW-0.169*AGE; intercompartmental clearance (Q, 1 h(-1)) = 4.27*(1-0.355*GEN); oral absorption rate constant (ka(p.o.), h(-1)) = 4.70-0.0439*DOSE*(1-0.507*FED); intramuscular absorption rate constant (ka(i.m.), h(-1)) = 0.122*DOSE; relative bioavailability (F) = 93.4%; and oral absorption lag time (LAG(p.o.), min) = 13.5. Pharmacokinetic parameters (%CV) for a typical fasted male subject in this study were CL, 7.341 h(-1) (27%); Vc, 23.51 (28%); Vp, 25.31 (31%); Q, 4.25 1 h(-1) (41%); ka(p.o.), 3.67 h(-1) (77%); and ka(i.m.), 3.09 h(-1) (44%). CONCLUSIONS The population pharmacokinetics of methotrexate in adults with rheumatoid arthritis were well described by this investigation. Substantial interpatient variability was explained by incorporating patient specific data into regression equations predicting pharmacokinetic parameters.

[1]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[2]  J. Kremer,et al.  Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. , 1995, The Journal of rheumatology.

[3]  F. Jamali,et al.  Low‐dose methotrexate kinetics in arthritis , 1984, Clinical pharmacology and therapeutics.

[4]  B. Bannwarth,et al.  Clinical Pharmacokinetics of Low-Dose Pulse Methotrexate in Rheumatoid Arthritis , 1996, Clinical pharmacokinetics.

[5]  J. Kremer,et al.  Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. , 1992, Arthritis and rheumatism.

[6]  J. Kisicki,et al.  The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. , 1992, Arthritis and rheumatism.

[7]  M. Weinblatt,et al.  Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. , 1992, Arthritis and rheumatism.

[8]  D. Furst,et al.  Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. , 1989, The Journal of rheumatology.

[9]  D. Furst,et al.  Biliary elimination of low-dose methotrexate in humans. , 1990, Arthritis and rheumatism.

[10]  G. Koren,et al.  Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. , 1990, The Journal of rheumatology.

[11]  W. Evans,et al.  Aspirin alters methotrexate disposition in rheumatoid arthritis patients. , 2010, Arthritis and rheumatism.

[12]  A. Russell,et al.  Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. , 1990, The Journal of rheumatology.

[13]  L B Sheiner,et al.  Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.

[14]  W. Spruill,et al.  Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[15]  C. Bologna,et al.  Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. , 1997, The Journal of rheumatology.

[16]  J. Kremer,et al.  The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. , 1995, The Journal of rheumatology.

[17]  J. Kremer,et al.  A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months. , 1988, Arthritis and rheumatism.

[18]  P. Seideman.  Methotrexate--the relationship between dose and clinical effect. , 1993, British journal of rheumatology.

[19]  D. Furst,et al.  Effect of aspirin and sulindac on methotrexate clearance. , 1990, Journal of pharmaceutical sciences.

[20]  M. Weinblatt,et al.  Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[21]  C. Bologna,et al.  Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. , 1995, British journal of rheumatology.

[22]  J. Bertino,et al.  Methotrexate pharmacokinetics in patients with rheumatoid arthritis. , 1989, The Journal of rheumatology.

[23]  J. Kremer,et al.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[24]  W. Evans,et al.  Coadministration of naproxen and low‐dose methotrexate in patients with rheumatoid arthritis , 1990, Clinical pharmacology and therapeutics.

[25]  D. Furst,et al.  Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. , 1989, Journal of pharmaceutical sciences.

[26]  P. Lafforgue,et al.  Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. , 1995, The Journal of rheumatology.

[27]  J. Reichen,et al.  Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[28]  P. Marquet,et al.  Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. , 1995, International journal of clinical pharmacology and therapeutics.